Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (314)	2/12/2004 6:03:31 PM
From: Icebrg	Read Replies (1) \| Respond to of 590

Raven Names Stephen Worsley Vice President, Business Development Thursday February 12, 4:52 pm ET Company Ramps Up Alliance Activities [No more business to develop at Abgenix?] SOUTH SAN FRANCISCO, Calif., Feb. 12 /PRNewswire/ -- Raven biotechnologies, inc. announced today the appointment of Stephen Worsley to the position of Vice President, Business Development. Mr. Worsley will direct the expansion of Raven's corporate alliances for research and product development and will oversee licensing and new business development activities as Raven steps up efforts to advance tumor-specific monoclonal antibody (MAb) candidates into clinical development. "Raven is entering a phase in which business partnerships will become central to our strategy," said Jennie Mather, PhD, President and CEO of Raven. "Stephen has an impressive track record of identifying and forging relationships with industry partners in the biotechnology and pharmaceutical industries, with specific experience in monoclonal antibody business development. He will be a tremendous asset to Raven as we explore multiple opportunities to build our business through strategic licensing agreements and product development collaborations." Mr. Worsley's experience in senior licensing and business development positions in the biotechnology industry spans more than 12 years. Most recently, Mr. Worsley was Director of Business Development at Abgenix, Inc., where he was responsible for commercial and business development activities. During his tenure, he executed several joint venture agreements including the outlicensing of the company's flagship antibody product candidates, ABX-EGF and ABX-CBL; managed platform technology outlicensing deals involving the XenoMouse® technology with major pharmaceutical and biotechnology companies; and executed a number of in-licensing alliances with major biotechnology companies involving late-stage validated targets.